DreaMed

DreaMed is a healthcare technology company focused on AI-driven solutions for diabetes management. Founded in 2014 and based in Israel, DreaMed initially developed artificial pancreas technology and has since expanded to include AI-based clinical decision support systems. The company aims to improve diabetes treatment accessibility worldwide by offering expert-level care recommendations through its proprietary algorithms. DreaMed's core products include Advisor Pro, an FDA-cleared AI platform that provides personalized insulin therapy recommendations for type 1 diabetes patients, and endo.digital, which optimizes insulin treatment plans for both type 1 and type 2 diabetes patients. The company also developed an artificial pancreas algorithm that has been integrated into Medtronic's Minimed 780G insulin pump system. DreaMed's solutions are clinically validated and utilized in leading healthcare institutions, addressing the global shortage of endocrinologists and enhancing diabetes care for patients.

Hospital & Health Care Petah Tikva, Israel ~39 employees

Work at DreaMed in HR or recruiting? Claim this page

Employees
39
+5.4% in the 3 months to Apr 2025
Total funding
$10.3M
Last round Sep 2020
12-month attrition
0%
Tech: 0%
H1B sponsor
NA

Headcount trend

DreaMed went from 29 employees in May 2023 to 39 in Apr 2025. Nov 2024 to Apr 2025: 3 people joined, 0 left.

Headcount data through Apr 2025

Funding rounds

Total funding$10.3M
Funding rounds3
Investors2
DateRoundMoney raisedNo.Investors
Sep 2020Funding$5M1
Jul 2016Venture$3.3M––
Apr 2015Seed$2M1

Org structure

Headcount by department

Other13
Engineering12
Operations5
HR3
Success2
Sales1
Finance1
Product1

DreaMed FAQ

How many employees does DreaMed have?

DreaMed has about 39 employees, up 5.4% over the 3 months to Apr 2025.

How much funding has DreaMed raised?

DreaMed has raised $10.3M in total funding.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.